Come win with BAD BEAT Investing. It is TIME. TRY BAD BEAT for 55% off the trial price, $199 marked down to $87. Why join?We have been following the UnitedHealth Group Incorporated ( UNH ) story now for about a year. 2025 was a whirlwind, for sure. We saw huge management shifts. We saw the company mis-model the expected usage and costs whenThe Pioneer Of Seeking Alpha's BAD BEAT Investing, Quad 7 Capital is a team of 7 analysts with a wide range of experience sharing investment opportunities for nearly 12 y ...

Come win with BAD BEAT Investing. It is TIME. TRY BAD BEAT for 55% off the trial price, $199 marked down to $87. Why join?We have been following the UnitedHealth Group Incorporated ( UNH ) story now for about a year. 2025 was a whirlwind, for sure. We saw huge management shifts. We saw the company mis-model the expected usage and costs whenThe Pioneer Of Seeking Alpha's BAD BEAT Investing, Quad 7 Capital is a team of 7 analysts with a wide range of experience sharing investment opportunities for nearly 12 y ...

UnitedHealth ( UNH ) was one of the worst performing financial stocks of 2025. Down nearly 35% for the year, it vastly underperformed the S&P 500, which eked out a solid gain for theAnalyst’s Disclosure:I/we have a beneficial long position in the shares of UNH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whos ...

In an election year, Washington, D.C. focused on Medicare Advantage oversight, and UnitedHealth Group (UNH) has become a prime target. Senators Elizabeth Warren and Ron Wyden have escalated their investigation into the company’s nursing home practices after reports and whistleblower claims that some seniors allegedly died when hospital transfers were delayed or denied under UnitedHealth-linked Medicare plans. At the same time, federal agencies are tightening audits of Medicare Advantage contracts and bil ...

Core Viewpoint - The U.S. Senate committee has found that UnitedHealth (UNH.US) employed "aggressive strategies" to collect diagnostic information from its Medicare Advantage members to increase payments, turning risk adjustment into a business, which was not its original intent [1] Group 1: Investigation Findings - A new report based on a review of 50,000 pages of records submitted by UnitedHealth to the U.S. Senate Judiciary Committee revealed that the company systematically added diagnostic information to patient records to secure billions of dollars in additional federal funding [1] - Some of the added diagnoses were questioned for their accuracy, and many patients appeared not to have received treatment for these newly added conditions [1] Group 2: Ongoing Investigations - UnitedHealth is facing multiple investigations regarding its business practices, including civil and criminal investigations disclosed by the Department of Justice in July [1] Group 3: Company Response - A spokesperson for UnitedHealth disagreed with the Senate report's characterization, stating that the company complies with Medicare requirements and has performed well in diagnostic audits [1] - The spokesperson emphasized the company's commitment to providing lower-cost, more convenient, and higher-quality healthcare services to its Medicare Advantage population [1]

Health insurer UnitedHealth Group used aggressive tactics to gather diagnoses that can boost Medicare Advantage payments, the Wall Street Journal reported on Monday, citing a U.S. Senate committee investigating the company's practices. ...

Sen. Chuck Grassley launched an investigation last year following Wall Street Journal reports examining the company's Medicare Advantage practices. ...

本文源自：金融界AI电报 杰富瑞：将联合健康(UNH.N)目标价从115美元上调至118美元。 ...

Core Insights - The "High-Income DIY Portfolios" Marketplace service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees or near-retirees [1][2] - The service offers a total of 10 model portfolios, including 3 buy-and-hold, 3 rotational portfolios, and a conservative NPP strategy portfolio, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1 - The service includes two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy portfolio that focuses on low drawdowns and high growth [1] - The unique 3-basket investment approach aims for 30% lower drawdowns, 6% current income, and market-beating growth over the long term [2] - The portfolios are structured to cater to varying levels of risk and include buy and sell alerts along with live chat support for investors [2]

Core Viewpoint - Healthcare investing offers defensive characteristics during market turbulence, but regulatory uncertainty and political risk can lead to sudden selloffs [1] Group 1: Fund Overview - Fidelity MSCI Health Care Index ETF (FHLC) tracks the MSCI USA IMI Health Care Index, providing exposure to U.S. healthcare companies across various sectors [2] - The fund has an expense ratio of 0.084%, which is lower than many competitors, while maintaining over 80 holdings [2] - FHLC's return is driven by capital appreciation from underlying stock holdings and modest dividend income from mature healthcare companies [2] Group 2: Concentration Risk - Eli Lilly (NYSE:LLY) constitutes over 13% of FHLC's portfolio, linking the fund's performance closely to GLP-1 obesity drugs [3] - The stock of Eli Lilly has surged 46% over the past year and is trading near its 52-week high [3] - The top five holdings also include UnitedHealth (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) [3] Group 3: Performance Analysis - FHLC has gained 5.3% over the past month and 17.9% over the past year, outperforming the S&P 500 in both periods [4] - However, over five years, FHLC returned 42.6% compared to the S&P 500's 84.5%, and over ten years, the gap widens to 154% versus 235% [4] - This long-term underperformance is attributed to challenges in the healthcare sector, including drug pricing pressures and slower innovation cycles [5] Group 4: Future Considerations - Recent momentum in FHLC suggests potential sector rotation, but buying after outperformance carries inherent risks [5] - Enhanced ACA premium tax credits have an 87.5% probability of expiring by January 31, 2026 [6]